Artemisinin IV Infusion Therapy (TGM New)

Breast Cancer

Breast cancer cells often have higher intracellular iron levels due to increased metabolic activity, making them particularly susceptible to artemisinin’s mechanism of action, which relies on the generation of reactive oxygen species (ROS) when it binds to iron.

Artemisinin has been shown to inhibit cell proliferation, induce apoptosis (programmed cell death), and reduce the viability of breast cancer cells, particularly triple-negative breast cancer (TNBC), a subtype known for its aggressive nature.

Potential Benefits:
Enhancement of Chemotherapy: Artemisinin can potentially sensitize breast cancer cells to chemotherapy, reducing the required dose of chemotherapeutic agents and minimizing side effects.
Inhibition of Metastasis: Some studies suggest that artemisinin may reduce migration and invasion of breast cancer cells, potentially limiting the metastatic spread to distant organs, a common challenge in advanced breast cancer.

Ovarian Cancer

Ovarian cancer, particularly high-grade carcinoma, is often diagnosed at an advanced stage due to its subtle symptoms and rapid metastasis.

Like other cancers, ovarian cancer cells often accumulate excessive iron, which makes them particularly vulnerable to the ROS generated by artemisinin’s peroxide bridge.

Potential Benefits:
Tumour Growth Suppression: Artemisinin has shown efficacy in inhibiting the growth of ovarian cancer cells by inducing apoptosis and disrupting cell cycles.
Combination with Chemotherapy: Given that ovarian cancer often responds to platinum-based chemotherapy (e.g., cisplatin), artemisinin may act synergistically with these agents, improving their effectiveness and overcoming chemoresistance.
Enhanced Immune Response: Artemisinin has been reported to enhance the activity of immune cells, such as T-cells and natural killer (NK) cells, which could improve the body’s ability to target and eliminate ovarian cancer cells.

Colon Cancer

Colon cancer cells are known to have altered iron metabolism, which makes them prime targets for artemisinin’s ROS-inducing effects.

Artemisinin has been shown to inhibit colon cancer cell proliferation and induce cell cycle arrest, preventing further tumour growth.

Potential Benefits:
Tumour Regression: In preclinical models, artemisinin has demonstrated the ability to reduce the size of colon tumours and prevent the spread of cancerous cells to other parts of the body.
Synergy with Conventional Therapies: Studies suggest that combining artemisinin with chemotherapy or radiation therapy may improve the overall effectiveness of treatment, especially in advanced-stage colon cancer.
Inhibition of Angiogenesis: Artemisinin may reduce angiogenesis (the formation of new blood vessels), which is critical for tumour survival and growth in colon cancer.

Prostate Cancer

Prostate cancer cells, particularly androgen-independent cancer cells (those that do not respond to hormonal therapy), often exhibit increased iron content. This makes them susceptible to artemisinin’s cytotoxic effects, which generate oxidative stress and cause damage to the cancer cells.

Potential Benefits:
Inhibition of Prostate Cancer Cell Growth: Artemisinin has been found to inhibit the growth of both androgen-dependent and androgen-independent prostate cancer cells, potentially offering a therapeutic approach for advanced prostate cancer.
Synergistic Effects with Hormonal Therapy: When combined with androgen deprivation therapy (ADT) or other conventional treatments such as chemotherapy, artemisinin may improve response rates and reduce the risk of recurrence.

Artemisinin IV therapy could be an important adjunct for hormone-refractory prostate cancer (cancer that no longer responds to hormonal treatment), supporting to improve outcomes and delay disease progression).

Lung Cancer

Lung cancer cells, especially those in non-small cell lung cancer (NSCLC), often exhibit increased iron uptake and oxidative stress, making them vulnerable to artemisinin’s action.

Research has indicated that artemisinin induces apoptosis in lung cancer cells by increasing ROS levels and interfering with cellular signalling pathways that promote survival.

Potential Benefits:
Chemoresistance Reversal: In chemotherapy-resistant lung cancers, artemisinin may enhance the cytotoxic effects of common chemotherapy drugs (e.g., paclitaxel or cisplatin), restoring sensitivity to treatment.
Inhibition of Tumour Metastasis: Artemisinin has demonstrated anti-metastatic effects in lung cancer models by reducing the ability of cancer cells to migrate and invade surrounding tissues.

Glioblastoma Multiforme (GBM)

Glioblastoma multiforme is a highly aggressive brain tumor characterized by rapid growth and resistance to conventional therapies. Artemisinin’s ability to induce oxidative stress and target cancer cells via the iron-mediated pathway offers a potential novel approach for treating GBM.

Potential Benefits:
Selective Cytotoxicity: Artemisinin targets glioblastoma cells while minimizing damage to surrounding healthy tissues, which is particularly important for brain tumours where precision is crucial.
Synergism with Chemotherapy: In combination with standard treatments like temozolomide or radiation, artemisinin could improve survival rates by enhancing the tumour’s vulnerability to these therapies.
Blood-Brain Barrier Penetration: Artemisinin derivatives artesunate may have the potential to cross the blood-brain barrier (BBB), delivering therapeutic benefits directly to brain tumours.